DDInter1033 DDInter1763
Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999.
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Leflunomide {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Leflunomide {u} (Compound) upregulates {v} (Gene) WIF1
WIF1 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Leflunomide {u} (Compound) downregulates {v} (Gene) CD320
CD320 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Leflunomide {u} (Compound) causes {v} (Side Effect) Ecchymosis
Ecchymosis {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Leflunomide {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Leflunomide {u} (Compound) upregulates {v} (Gene) WIF1
WIF1 {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Leflunomide {u} (Compound) downregulates {v} (Gene) CD320
CD320 {u} (Gene) is downregulated by {v} (Compound) Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Leflunomide {u} (Compound) causes {v} (Side Effect) Ecchymosis
Ecchymosis {u} (Side Effect) is caused by {v} (Compound) Tacrolimus
Tacrolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Leflunomide {u} (Compound) resembles {v} (Compound) Niflumic Acid
Niflumic Acid {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Leflunomide {u} (Compound) upregulates {v} (Gene) WIF1
WIF1 {u} (Gene) is regulated by {v} (Gene) MTOR
MTOR {u} (Gene) is bound by {v} (Compound) Temsirolimus
Leflunomide may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Leflunomide (Compound) upregulates WIF1 (Gene) and WIF1 (Gene) is upregulated by Temsirolimus (Compound)
Leflunomide (Compound) downregulates CD320 (Gene) and CD320 (Gene) is downregulated by Temsirolimus (Compound)
Leflunomide (Compound) causes Ecchymosis (Side Effect) and Ecchymosis (Side Effect) is caused by Temsirolimus (Compound)
Leflunomide may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Leflunomide (Compound) upregulates WIF1 (Gene) and WIF1 (Gene) is upregulated by Sirolimus (Compound) and Sirolimus (Compound) resembles Temsirolimus (Compound)
Leflunomide (Compound) downregulates CD320 (Gene) and CD320 (Gene) is downregulated by Sirolimus (Compound) and Sirolimus (Compound) resembles Temsirolimus (Compound)
Leflunomide (Compound) causes Ecchymosis (Side Effect) and Ecchymosis (Side Effect) is caused by Tacrolimus (Compound) and Tacrolimus (Compound) resembles Temsirolimus (Compound)
Leflunomide (Compound) resembles Niflumic Acid (Compound) and Niflumic Acid (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Temsirolimus (Compound)
Leflunomide (Compound) upregulates WIF1 (Gene) and WIF1 (Gene) is regulated by MTOR (Gene) and MTOR (Gene) is bound by Temsirolimus (Compound)